Fisher & Paykel Healthcare Corp Ltd stock (NZFAPE0001S2): Rich valuation amid solid earnings beat

Fisher & Paykel Healthcare Corp Ltd (NZX:FPH) shares are trading at a rich valuation multiple despite a recent earnings beat, as analysts at Morgan Stanley have trimmed their target prices for the stock. The company’s latest half?year results showed earnings per share of NZ$0.36, topping consensus expectations of NZ$0.34 and implying a positive surprise of about 5.26%, according to TradingView data as of May 2026.

At the same time, Morgan Stanley has cut its target price for Fisher & Paykel Healthcare by roughly 9.5% to NZ$40.00 per share and by about 12% to A$32.80 per share, reflecting a more cautious stance on the stock’s upside potential, according to moomoo news posts dated May 2026. The current share price of around NZ$35.75 implies that the stock trades at a price?to?earnings ratio of about 48x, which is well above both the broader medical?equipment industry average of 25x and a peer?group average of roughly 39x, according to Simply Wall St analysis as of May 2026.

As of: 08.05.2026

By the editorial team – specialized in equity coverage.

Fisher & Paykel Healthcare Corp Ltd: core business model

Fisher & Paykel Healthcare Corp Ltd designs, manufactures and sells a range of respiratory and acute?care medical devices used in hospitals and home?care settings. The company’s portfolio includes humidification systems, ventilator circuits, sleep?apnea therapy devices and other respiratory?support products that help manage chronic obstructive pulmonary disease, sleep?disordered breathing and critical?care conditions. Its business model combines recurring revenue from consumables and disposables with higher?margin capital equipment sales, which together support relatively stable cash flows.

The company targets both institutional and home?care channels, with a focus on improving patient outcomes through integrated therapy systems and digital?enabled monitoring. Fisher & Paykel Healthcare’s products are distributed through a global network of distributors and direct sales teams, giving it exposure to multiple regions and healthcare systems. This diversified channel structure helps mitigate concentration risk in any single market, while also enabling the firm to capture growth in emerging?market healthcare spending.

Main revenue and product drivers for Fisher & Paykel Healthcare Corp Ltd

Respiratory?care products remain the primary revenue driver for Fisher & Paykel Healthcare Corp Ltd, with humidification systems and ventilator circuits accounting for a substantial share of sales. These products are used in intensive?care units, operating theatres and long?term ventilation settings, where clinicians rely on consistent humidification to reduce complications and improve comfort. The company’s proprietary heated?humidification technology differentiates its offerings and supports premium pricing versus generic alternatives.

Sleep?apnea therapy devices and related accessories represent another key growth segment, benefiting from rising awareness of obstructive sleep apnea and expanding home?care adoption. Fisher & Paykel Healthcare’s sleep?therapy portfolio includes masks, tubing and humidifiers that integrate with continuous positive airway pressure (CPAP) and bilevel devices. In addition, the firm’s acute?care solutions, such as non?invasive ventilation circuits and oxygen?therapy systems, contribute to revenue in hospital settings and during respiratory?season peaks.

Why Fisher & Paykel Healthcare Corp Ltd matters for US investors

For US investors, Fisher & Paykel Healthcare Corp Ltd offers indirect exposure to global respiratory?care demand and the broader medical?device sector without direct listing on a US exchange. The company derives a meaningful portion of its revenue from North America, including the United States, where aging demographics, high prevalence of chronic respiratory conditions and ongoing hospital?care spending support demand for advanced respiratory?support products. This regional exposure links the stock’s performance to trends in US healthcare utilization and reimbursement policies.

Moreover, the firm’s premium valuation multiple and relatively high earnings?quality profile make it a reference point for investors assessing medical?equipment peers listed in the United States. US?based investors can access Fisher & Paykel Healthcare through NZX?listed shares or via international brokerage platforms, though currency and liquidity considerations should be factored into any allocation decision.

Conclusion

Fisher & Paykel Healthcare Corp Ltd continues to deliver solid earnings performance, as evidenced by its recent half?year results that beat consensus expectations. However, the stock trades at a premium valuation multiple relative to both the medical?equipment industry and its peer group, which has prompted analysts to trim target prices and flag a potentially rich risk?reward profile. For investors, this combination of strong fundamentals and elevated multiples underscores the importance of careful valuation assessment and diversification.

US investors considering Fisher & Paykel Healthcare should weigh the company’s global respiratory?care exposure and recurring?revenue characteristics against currency risk, liquidity constraints and the possibility of further multiple compression if growth expectations are not met. As with any equity investment, a balanced view that incorporates both the company’s competitive strengths and the current valuation environment is advisable before making any allocation decisions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.